Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 8/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407507 | 0.91 | MTNR1B (0.46) | SLC6A5MTNR1BHRH3 | |
| SCHEMBL22411105 | 0.89 | MAOA (0.47) | SLC6A5MAOBMAOAMTNR1BHRH3 | |
| SCHEMBL6403218 | 0.86 | MTNR1B (0.50) | SLC6A5MAOBMAOAMTNR1B | |
| SCHEMBL6403876 | 0.82 | ADRA1D (0.46) | SLC6A5MTNR1BHRH3KCNH2 | |
| SCHEMBL6404770 | 0.81 | HTR2C (0.50) | SLC6A5MTNR1BHRH3 | |
| SCHEMBL6404942 | 0.80 | SIGMAR1 (0.49) | MTNR1BHRH3MCHR1 | |
| SCHEMBL6410620 | 0.78 | HRH3 (0.50) | MAOBMAOAMTNR1BHRH3KDM1A | |
| SCHEMBL6407452 | 0.78 | MTNR1B (0.52) | SLC6A5MTNR1B | |
| SCHEMBL6001733 | 0.76 | MTNR1B (0.50) | MTNR1B | |
| SCHEMBL6001623 | 0.76 | MTNR1B (0.70) | MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | claimed |
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005113527-A1 | TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS | PFIZER PRODUCTS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | HTR1A, HTR1B, HTR1D | SLC6A5 976/4885MAOB 120/4885MAOA 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.